A California jury has awarded $40 million in damages to two women who claimed that long-term use of Johnson & Johnson’s talc-based baby powder caused their ovarian cancer, marking a significant development in the company’s ongoing talc litigation. The verdict was delivered Friday in Los Angeles Superior Court, where jurors concluded that Johnson & Johnson knew for decades about potential cancer risks associated with its baby powder products but failed to warn consumers.
The jury awarded $18 million to Monica Kent and $22 million to Deborah Schultz and her husband. Both women are California residents who testified that they used Johnson & Johnson baby powder daily after bathing for roughly 40 years. Kent was diagnosed with ovarian cancer in 2014, while Schultz received her diagnosis in 2018. According to trial testimony, both women underwent extensive medical treatment, including major surgeries and numerous rounds of chemotherapy.
During closing arguments, plaintiffs’ attorney Andy Birchfield told jurors that internal company knowledge about cancer risks linked to talc dated back to the 1960s. He argued that Johnson & Johnson deliberately concealed this information to protect sales. The jury ultimately agreed, finding the company liable for failing to warn consumers about potential dangers.
Johnson & Johnson has strongly denied the claims and announced plans to immediately appeal the verdict. Erik Haas, the company’s worldwide vice president of litigation, said the company expects to prevail, arguing that the decision represents an “aberrant adverse verdict.” Defense attorney Allison Brown told jurors that no major U.S. health authority has established a causal link between talc use and ovarian cancer, and that no scientific study proves talc can migrate to reproductive organs.
Johnson & Johnson is currently facing more than 67,000 lawsuits related to its talc products, the majority involving ovarian cancer claims. The company stopped selling talc-based baby powder in the United States in 2020, switching to a cornstarch alternative. Efforts to resolve the litigation through bankruptcy have been rejected multiple times by federal courts, allowing cases to resume.
The verdict underscores the ongoing legal and financial risks Johnson & Johnson faces as talc cancer lawsuits continue to move forward in courts across the country.


Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten
BHP Shares Fall as Jansen Potash Project Costs Surge
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples
DOJ Opens Criminal Investigation Into E. Jean Carroll Over Alleged Perjury
Florida Supreme Court Allows GOP Congressional Map to Stand Ahead of 2026 Midterm Elections
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race
Bayer Rules Out Monsanto Spin-Off as Roundup Lawsuits Continue to Mount
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court
Biden Sues DOJ to Block Release of Audio From Classified Documents Probe
DOJ Pushes to Resume Trump White House Ballroom Project After Security Incident
Sable Offshore Wins Key Court Battle Over California Oil Pipeline
Trump Says Anthropic No Longer Seen as National Security Threat
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 



